Improving the Antigenicity of SARS-CoV-2 Vaccine Genes by Merging Mutations from Different Variants of Concern

Susanne Herwig,Julia M. Adler,Daria Vladimirova,Jakob Trimpert,Jalid Sehouli,Günter Cichon

DOI: https://doi.org/10.3390/vaccines12030248

2024-02-28

Vaccines

Abstract:During the COVID-19 pandemic, the early emergence of viral variants repeatedly undermined the effects of vaccination. Our aim here is to explore strategies for improving spike vaccine gene antigenicity by merging mutations from different variants of concern (VOCs) in a single vaccine gene. To this end, newly developed recombinant vaccine genes were designed, cloned into adenoviral vectors, and applied to C57BL/6 mice; then, serum-neutralizing antibodies against the wildtype SARS-CoV-2 strains were determined in neutralization assays. The merger of mutations from different variants of concern (alpha, beta, gamma, and delta) in a single recombinant spike-based vaccine gene provided a substantial improvement in neutralizing immunity to all variants of concern, including the omicron strains. To date, only unmodified spike genes of the original SARS-CoV-2 Wuhan strain (B.1) or dominant variants (BA.1, BA.5, and XBB.1.5) have been used as vaccine genes. The employment of unmodified vaccine genes is afflicted by limited cross-protection among variant strains. In contrast, recombinant vaccine genes that combine mutations from different strains in a single gene hold the potential to broaden and improve immune protection and might help to reduce the need for frequent vaccine adaptations in the future.

immunology,medicine, research & experimental

What problem does this paper attempt to address?

### The Problem the Paper Attempts to Solve

The paper aims to enhance the antigenicity of SARS-CoV-2 vaccine genes by incorporating mutations from different variants of concern (VOCs). Specifically, the researchers designed new recombinant vaccine genes and cloned them into adenoviral vectors, which were then applied in mouse experiments. The experimental results showed that incorporating mutations from different variants of concern (such as Alpha, Beta, Gamma, and Delta) into a single recombinant spike protein gene can significantly improve the neutralizing immune response against all variants of concern, including the Omicron variant.

Currently used vaccine genes are primarily unmodified original SARS-CoV-2 Wuhan strain (B.1) or major variants (such as BA.1, BA.5, and XBB.1.5) spike genes, which provide limited cross-protection between different variants. In contrast, recombinant vaccine genes that combine mutations from different variants have the potential to enhance and improve immune protection, which may help reduce the need for frequent vaccine adjustments in the future.